mana.bio

Mana.bio is an AI-based biotechnology startup founded in 2021, focused on enhancing targeted gene therapy delivery.

The company combines machine learning with lipid nanoparticle (LNP) engineering to create solutions for drug delivery beyond the liver. Its proprietary platform is designed for programmable LNPs that support various oligonucleotide therapies, including RNA and DNA-based therapeutics, vaccines, and CRISPR gene editing tools. The core service of Mana.bio is its AI-driven LNP discovery platform, which utilizes a high-throughput Design-Build-Test-Learn cycle to identify optimal LNP formulations for specific payloads. The company also launched MinaTM, a large language model specifically for lipid nanoparticles, aimed at accelerating scientific discovery. Mana.bio collaborates with biotechnology and pharmaceutical companies to optimize formulations for cell-specific delivery, addressing significant challenges in gene therapy. Headquartered in Tel Aviv, Israel, the company has raised $19.5 million in funding and employs a team of experts in drug delivery, machine learning, and software development.